11 years ago

September 10, 2013, Luxembourg –

Hultquist IP client Advanced Biological Laboratories SA (Luxembourg) today announced the signing of a collaboration agreement with Roche Diagnostics International to promote their next-generation sequencing, genotyping and drug resistance products. The agreement covers Europe, Metal East, Africa, and Latin America territories, and involves ABL’s next-generation sequencing platform DeepChek® and Roche’s GS Junior and GS FLX+ systems for molecular virology. The collaboration will provide integrated sequencing and analysis systems for personalized healthcare applications.

Roche is the world’s largest biotechnology company, and is actively engaged in developing pharmaceuticals and diagnostics in the fields of oncology, infectious disease, inflammation, metabolism, and neuroscience.

ABL originated in 2000 as a spin-off of the European academic research center, CRP-SantéLuxembourg, and most recently acquired viral hepatitis-related business and intellectual property assets of Evivar Medical, a spinoff of Melbourne Health (Australia). ABL’s suite of healthcare management tools include TherapyEdge®, ViroScore®, SeqHepB™, DeepChek®, and VisibleChek® products utilized for data and patient management, monitoring, and personalized reporting applications.

Hultquist IP attorneys David Bradin and Steven Hultquist were engaged in the due diligence, negotiation, and contractual aspects of the Roche and Evivar transactions as intellectual property counsel to ABL. We are pleased to support the business and proprietary activities of ABL as it continues to develop and commercialize leading-edge products for the personalized healthcare industry.